Herpes simplex virus hides inside nerve cells, specifically in clusters of nerve cell bodies called sensory ganglia that sit just outside the spinal cord and brain. After an initial infection at the skin or mucous membranes, the virus travels along nerve fibers in the reverse direction from normal nerve signals, reaching these ganglia and settling into a dormant state called latency. This is not a temporary pause. The viral DNA persists in those neurons for life, kept quiet by a combination of the cell’s own chemistry and constant immune surveillance, but never fully eliminated.
Which Ganglia and Why Those Ones
The specific ganglia where herpes sets up residence depend on where the initial infection happens. HSV-1, which typically causes oral herpes, favors the trigeminal ganglia, a pair of nerve clusters located near the base of the skull that relay sensation from the face, lips, and eyes. Autopsy studies have found latent HSV-1 in the trigeminal ganglia of the majority of adults examined, including people who had no active herpes infection at the time of death.1PubMed Central. Latent herpesvirus infection in human trigeminal ganglia causes chronic immune response One study used a technique called in situ hybridization to detect HSV-1 gene activity in trigeminal ganglia from 24 autopsy subjects with no sign of active herpes, confirming the virus was silently present.2PubMed. Latent herpes simplex virus in human trigeminal ganglia. Detection of an immediate early gene “anti-sense” transcript by in situ hybridization
HSV-2, the type more commonly associated with genital herpes, parks itself in the sacral dorsal root ganglia, which are nerve clusters near the base of the spine serving the genital and pelvic region. Latent HSV-2 DNA and its characteristic RNA transcripts have been identified in human sacral ganglia, and the ability of the virus to reactivate from this location is the biological basis for recurrent genital outbreaks.3PubMed. Characterization of herpes simplex virus type 2 latency-associated transcription in human sacral ganglia and in cell culture Researchers have even used deep sequencing to catalog the small RNA molecules HSV-2 produces in these ganglia while dormant, giving a detailed molecular picture of what the virus does while hiding.4PubMed Central. Identification of viral microRNAs expressed in human sacral ganglia latently infected with herpes simplex virus 2
The virus specifically targets sensory neurons, not other types of nerve cells or random tissues. Sensory neurons are ideal hosts because they are long-lived (most persist for your entire life without being replaced), they are relatively sheltered from immune attack, and their structure provides a ready-made highway between the skin and the nervous system. The virus exploits this architecture both when it initially retreats inward and when it later reactivates and travels back outward.
How the Virus Reaches Its Hiding Spot
After infecting skin or mucosal cells at the surface, the virus enters the tips of nearby sensory nerve fibers. From there, it hitches a ride on the cell’s own transport machinery. Nerve cells are extraordinarily long, with fibers (axons) that can stretch considerable distances from the skin surface to the ganglion. The virus needs to travel the full length of the axon in the “wrong” direction, heading inward toward the nerve cell body rather than outward toward the periphery. This inward journey is called retrograde transport.
The viral capsid, stripped of most of its outer coat, travels along internal tracks within the axon called microtubules. It is accompanied by specific viral proteins that help it latch onto the cell’s motor proteins, which act like tiny molecular trucks hauling cargo along the microtubule track.5Frontiers in Cellular Neuroscience. Herpes Simplex Virus Type 1 Infection of the Central Nervous System: Insights Into Proposed Interrelationships With Neurodegenerative Disorders Studies on a related virus have clocked these capsids moving at speeds around one micrometer per second along microtubules, a pace that, given the scale of the axon, gets the virus to the cell body within hours.6Cell Host & Microbe. The Tegument Protein VP1/2 of Pseudorabies Virus Directs Retrograde Axonal Transport by Interacting with Dynein/Dynactin
Once it arrives at the cell body in the ganglion, the viral DNA enters the neuron’s nucleus and takes on a circular form. At this point, instead of hijacking the cell to produce more virus, the DNA essentially goes quiet. This transition from active replication to silence is the establishment of latency, and it marks the moment the virus becomes effectively invisible to most of the immune system and unreachable by antiviral drugs.
What Keeps the Virus Silent
The dormant viral DNA in a neuron is not truly dead or inert. A small region of the genome remains active, producing a molecule called the latency-associated transcript, or LAT. For years researchers debated what LAT actually does. The emerging picture is that it functions as a kind of self-imposed muzzle: LAT represses the expression of the virus’s own active genes, the ones it would need to switch on to begin replicating. Experimental work has shown that LAT reduces the frequency of reactivation at the level of individual neurons by broadly tamping down viral gene expression.7PubMed Central. The HSV-1 Latency-Associated Transcript Functions to Repress Latent Phase Lytic Gene Expression and Suppress Virus Reactivation from Latently Infected Neurons
LAT also appears to protect the neuron from dying. If the infected neuron were destroyed by normal cell-death pathways (a process called apoptosis), the virus would lose its hiding place. Research shows LAT inhibits apoptosis in part by interfering with immune signaling within the cell, keeping the host neuron alive and comfortable as a long-term reservoir.8PubMed Central. The Latency-Associated Transcript Inhibits Apoptosis via Downregulation of Components of the Type I Interferon Pathway during Latent Herpes Simplex Virus 1 Ocular Infection
Beyond what the virus does to itself, the host cell wraps the viral DNA in chemical modifications that silence it. During latency, the protein packaging around the viral DNA picks up marks characteristic of tightly wound, inactive genetic material. The virus’s active (lytic) genes become decorated with these repressive marks, keeping them firmly switched off.9PubMed Central. Epigenetic regulation of latent HSV-1 gene expression The prevailing model is that during an active infection the virus fights against this silencing, but during latency it acquiesces, allowing the cell to wrap its genome in silence. Reactivation, then, involves some disruption of that silencing.10PubMed Central. Chromatin-mediated epigenetic regulation of HSV-1 transcription as a potential target in antiviral therapy
The Immune System’s Standoff With the Virus
Latency is not maintained solely by the virus’s own molecular tricks. Your immune system plays a constant, active role. A specific type of immune cell, CD8+ T cells, congregates around latently infected ganglia and keeps the virus in check. These T cells use both lethal and non-lethal strategies: they can kill cells that start actively producing virus, and they can also suppress reactivation without destroying the neuron, using signaling molecules like interferon gamma.11PubMed. A triple entente: virus, neurons, and CD8+ T cells maintain HSV-1 latency When that CD8+ T cell surveillance is disrupted, reactivation of latent virus occurs.12PubMed Central. Immunological Control of Herpes Simplex Virus Type 1 Infection: A Non-Thermal Plasma-Based Approach
Sensory neurons themselves have some antiviral capacity, though it is weaker than that of most other cell types. While neurons have impaired built-in immune defenses against HSV, signaling from neighboring cells can ramp up a meaningful antiviral response within them. Autophagy, the cell’s garbage-disposal system for clearing damaged material, also contributes to neuronal control of the virus.13PubMed Central. Neurons versus herpes simplex virus: the innate immune interactions that contribute to a host-pathogen standoff The overall situation is best described as a standoff: the virus is not cleared, but it is held in a suppressed state by overlapping layers of control. Anything that tips the balance, whether illness, stress, immune suppression, or physical trauma, can allow the virus to wake up.
What Triggers Reactivation
Reactivation from latency can be set off by a range of physiological stresses. The list includes fever, UV sun exposure, physical trauma to the nerve, hormonal fluctuations, emotional stress, and suppression of the immune system. These different triggers do not all work through the same cellular pathway. Research using various laboratory models has identified both shared and distinct mechanisms by which different stimuli cause the latent virus to switch its lytic genes back on.14PubMed Central. Strength in diversity: Understanding the pathways to herpes simplex virus reactivation
When the virus does reactivate, newly assembled viral particles are built inside the neuron’s cell body and then shipped back down the axon toward the skin surface, reversing the original journey. This outward (anterograde) transport relies on a different set of motor proteins and requires specific viral surface proteins to recruit the transport machinery.15PubMed Central. The gE/gI complex is necessary for kinesin-1 recruitment during alphaherpesvirus egress from neurons Once the virus reaches the nerve endings in the skin or mucosa, it can infect epithelial cells and either cause a visible sore or shed silently without any noticeable symptoms.
Shedding Without Symptoms
One of the more unsettling aspects of herpes latency is that the virus frequently reactivates and reaches the skin surface without causing any visible outbreak. This is called asymptomatic shedding, and it is far more common than many people realize. A study of healthy adults found that when sensitive DNA detection methods were used, HSV-1 was present in the oral cavity on about a third of days sampled, with shedding rates among individuals ranging from roughly 11% to 63% of days tested.16PubMed Central. Herpes Simplex Virus Type 1 Shedding in Tears, and Nasal and Oral Mucosa of Healthy Adults The oral mucosa was the most frequent site, with widespread shedding throughout the mouth. Another review of data found HSV-1 DNA present in the oral cavity of over half of seropositive patients when measured across multiple visits.17PubMed. Asymptomatic shedding of herpes simplex virus (HSV) in the oral cavity
HSV-2 sheds similarly in the genital tract. Virus can be detected on genital surfaces even in people with no signs or symptoms of active disease, and transmission can occur during these silent episodes.18PubMed Central. Current Concepts for Genital Herpes Simplex Virus Infection: Diagnostics and Pathogenesis of Genital Tract Shedding This is the main reason herpes is so efficiently transmitted: a person does not need to have a visible cold sore or genital lesion to be infectious.
Why Antiviral Drugs Cannot Eliminate the Virus
Standard antiviral medications for herpes, like acyclovir and its relatives, work by blocking the virus’s ability to copy its DNA during active replication. They are effective at shortening outbreaks and reducing how often reactivation leads to symptoms. But they have a fundamental limitation: they only work on virus that is actively replicating. The latent viral DNA sitting quietly in a neuron’s nucleus is not replicating, so the drugs have nothing to target.
This has been demonstrated directly. In cell culture experiments, both acyclovir and penciclovir completely shut down productive HSV-1 infection in neurons, but neither drug prevented the virus from establishing latency. The percentage of neurons expressing the latency-associated transcript was the same whether or not the drugs were present, and when the drugs were removed, latent virus could be reactivated and produced the same amount of infectious virus as untreated controls.19PubMed. Lack of effect of treatment with penciclovir or acyclovir on the establishment of latent HSV-1 in primary sensory neurons in culture Acyclovir can suppress acute replication and reduce the frequency of reactivation, but it does not prevent the initial establishment of latency or clear a latent infection once it exists.20PubMed. Prevention of herpes simplex virus infection and latency by prophylactic treatment with acyclovir in a weanling mouse model
This is the core frustration for anyone hoping for a cure: the virus’s hiding spot in the nucleus of a long-lived neuron is simply beyond the reach of drugs designed to interfere with viral replication. A different strategy is needed, one that can find and disable or destroy the dormant DNA itself.
Gene Editing and the Search for a Cure
The most promising approaches to actually clearing latent herpes involve gene editing, using molecular tools delivered directly into ganglia to cut the viral DNA apart. Two main strategies are under active investigation. One uses engineered enzymes called meganucleases. In mouse experiments, a combination of meganucleases delivered by viral vectors achieved a roughly 97.7% reduction in HSV viral load in the dorsal root ganglia of mice with latent genital infections, the highest efficacy reported to date in that model.21Nature Communications. Gene editing for latent herpes simplex virus infection reduces viral load and shedding in vivo
A separate line of research uses CRISPR-Cas9, the more widely known gene-editing tool, to target sequences encoding essential HSV-1 proteins, aiming to disable the latent genome so it can never reactivate.22Molecular Therapy. CRISPR-Cas9 gene editing targets herpes simplex virus 1 latency in sensory ganglia Both approaches face significant hurdles in translating from mice to humans. Delivering gene-editing tools efficiently to enough neurons in human ganglia, avoiding off-target cuts to the person’s own DNA, and doing all this safely are formidable challenges. But the results so far represent the first time researchers have been able to meaningfully reduce the reservoir of latent virus rather than merely suppress its symptoms. Nanoparticle-based delivery systems are also being explored as a way to get latency-reversing or latency-disrupting agents into the right cells.23PubMed Central. Navigating Latency-Inducing Viral Infections: Therapeutic Targeting and Nanoparticle Utilization
Rare but Serious Reactivation in the Brain
Most of the time, herpes reactivation is a nuisance: a cold sore or a genital outbreak that heals within a couple of weeks. But in rare cases, the virus can reach the brain, causing herpes simplex encephalitis, a severe and potentially life-threatening inflammation. Even after appropriate treatment with acyclovir, proven viral reactivation causing relapsing disease has been observed in about 5% of pediatric cases, with fewer reports in adults. Some survivors carry detectable HSV DNA in the brain for years without obvious relapse, raising questions about whether low-level persistent infection contributes to long-term neurological effects.24Brain. The immunobiology of herpes simplex virus encephalitis and post-viral autoimmunity
Reactivation in the brain is especially concerning in people whose immune systems are compromised. Case reports have documented herpes encephalitis triggered by traumatic brain injury, likely because the immune suppression that follows major brain trauma allows latent virus to escape control. Clinicians treating brain-injured patients with unexplained fever and worsening neurological signs are encouraged to consider herpes reactivation as a possible cause.25PubMed. A rare case of herpes simplex virus encephalitis from viral reactivation following surgically treated traumatic brain injury
Other Herpesviruses Hide in Different Places
Herpes simplex is not the only virus in the herpesvirus family that establishes lifelong latency, and the different members have evolved to hide in strikingly different cell types. Varicella-zoster virus (the cause of chickenpox and shingles) also latches onto sensory ganglia, making it similar to HSV in that respect, though the details of what the virus does while dormant differ. Unlike HSV-1, which produces a single dominant transcript (LAT) during latency, varicella-zoster appears to express at least some viral proteins while dormant, blurring the line between true silence and low-level activity.26PubMed. Varicella-zoster virus latency in human ganglia Both viruses store their latent DNA in a circular form, and there is growing evidence that both are kept quiet by the same type of chemical DNA silencing.27PubMed Central. A comparison of herpes simplex virus type 1 and varicella-zoster virus latency and reactivation
Epstein-Barr virus, which causes mononucleosis and is linked to certain cancers, takes a completely different approach. It hides in memory B cells, a type of long-lived immune cell in the blood. Research showed that in the peripheral blood, the virus is restricted to a specific subset of B cells that have already been through the immune activation process.28PubMed. EBV persistence in memory B cells in vivo Because memory B cells are designed to survive for decades as part of normal immune memory, EBV gets a very long-lived host cell without having to infect a neuron.
Cytomegalovirus (CMV), another extremely common herpesvirus, hides in a different compartment entirely: bone marrow progenitor cells, the precursors that give rise to blood and immune cells. CMV DNA has been detected in bone marrow progenitor cells in the absence of active viral replication.29PubMed. Detection of endogenous human cytomegalovirus in CD34+ bone marrow progenitors The virus stays silent until these progenitor cells mature into certain immune cell types, at which point CMV can reactivate. This is why CMV reactivation is a major concern after bone marrow transplants: the transplant process itself disturbs the cellular compartment where the virus hides.30PubMed Central. Cytomegalovirus Latency and Reactivation: An Intricate Interplay With the Host Immune Response
An Ancient Relationship
The fact that herpes simplex virus has evolved such a sophisticated strategy for hiding in human neurons is not a recent development. Molecular analysis of HSV-1 and its closest primate relative suggests that HSV-1 has been co-evolving with the human lineage for roughly six million years, diverging from the chimpanzee herpes virus around the same time that the human and chimpanzee lineages split. HSV-2 has a more complicated history: rather than co-evolving with humans from an ancient common ancestor, it appears to have jumped from the ancestor of modern chimpanzees into an early human species around 1.6 million years ago.31PubMed Central. Evolutionary Origins of Human Herpes Simplex Viruses 1 and 2 A separate analysis using fossil and geographic data placed that cross-species jump between 1.4 and 3 million years ago, broadly consistent with the molecular estimate.32Virus Evolution. Network analysis of the hominin origin of Herpes Simplex virus 2 from fossil data
Millions of years of coexistence have shaped the virus’s latency strategy into something remarkably refined. The virus does not kill its host neuron, does not provoke an overwhelming immune response, and reactivates just often enough to spread to new hosts. From the virus’s perspective, the sensory ganglion is not merely a hiding spot but a carefully optimized long-term home, honed over evolutionary time to balance persistence with transmission.